NCT00591565View on ClinicalTrials.gov

An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants

NACompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Anxiety
Interventions
DRUG

Acamprosate

acamprosate 333mg tab, 3 by mouth 3 times a day

Trial Locations (1)

13210

SUNY Upstate Medical University Psychiatry Dept., Syracuse

Sponsors

Collaborators (1)

Forest Laboratories
All Listed Sponsors
collaborator

Forest Laboratories

INDUSTRY

lead

State University of New York - Upstate Medical University

OTHER